D
Donal J. Brennan
Researcher at Mater Misericordiae University Hospital
Publications - 150
Citations - 7861
Donal J. Brennan is an academic researcher from Mater Misericordiae University Hospital. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 42, co-authored 129 publications receiving 6598 citations. Previous affiliations of Donal J. Brennan include University College Dublin & Mater Health Services.
Papers
More filters
Journal ArticleDOI
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo,David G. DeNardo,Donal J. Brennan,Elton Rexhepaj,Brian Ruffell,Stephen L. Shiao,Stephen F. Madden,William M. Gallagher,Nikhil Wadhwani,Scott D. Keil,Sharfaa A. Junaid,Hope S. Rugo,E. Shelley Hwang,Karin Jirström,Brian L. West,Lisa M. Coussens +15 more
TL;DR: Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell-dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy.
Journal ArticleDOI
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Jonathan B. Mitchem,Donal J. Brennan,Brett L. Knolhoff,Brian A. Belt,Yu Zhu,Dominic E. Sanford,Larisa Belaygorod,Danielle Carpenter,Lynne Collins,David Piwnica-Worms,Stephen M. Hewitt,Girish Mallya Udupi,William M. Gallagher,Craig D. Wegner,Brian L. West,Andrea Wang-Gillam,Peter S. Goedegebuure,David C. Linehan,David G. DeNardo +18 more
TL;DR: These findings show how targeting TAMs can effectively overcome therapeutic resistance mediated by TICs and improve chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses.
Journal ArticleDOI
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward,Hagen Kulbe,Probir Chakravarty,David Leader,Vessela Vassileva,D. Andrew Leinster,Richard G. Thompson,Tiziana Schioppa,Jeffery Nemeth,Jessica Vermeulen,Naveena Singh,Norbert Avril,Jeffrey Cummings,Elton Rexhepaj,Karin Jirström,William M. Gallagher,Donal J. Brennan,Iain A. McNeish,Frances R. Balkwill +18 more
TL;DR: In this paper, the authors investigated whether inhibition of IL-6 has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network, and they combined pre-clinical and in silico experiments with a phase II clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
Survivin: A promising tumor biomarker
TL;DR: Emerging data suggests that measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis in multiple cancer types and predict response to diverse anti-cancer therapies.
Journal ArticleDOI
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.
Janna Paulsson,Tobias Sjöblom,Patrick Micke,Fredrik Pontén,Göran Landberg,Carl-Henrik Heldin,Jonas Bergh,Donal J. Brennan,Karin Jirström,Arne Östman +9 more
TL;DR: The prognostic significance of stromal PDGF beta-receptor expression was particularly prominent in tumors from premenopausal women and should be considered in ongoing clinical development of PDGF receptor inhibitors.